Detecting the Unseeable: Metastatic Prostate Cancer
"Molecular imaging can not only detect small amounts of disease for staging cancer, but also can be used to monitor how well treatment is working, and potentially to help us understand the biology of the disease in a particular patient," says Pomper. "We have a second-generation version of this compound that has recently completed toxicity studies, and we hope to move it fully to the clinic and test it against our original compound." In other work, Pomper's lab has developed a system for imaging and potentially treating prostate cancer. "It makes sense that if we can target these compounds with an imaging agent, we might also be able to target them with cancer-fighting drugs or radiation. In our preclinical studies, the imaging portion of this project has proven more sensitive than the current clinical standards." Graduate student Akrita Bhatnager, who works in Pomper's lab, recently presented this work at a joint meeting of the American Association for Cancer Research and the Society of Nuclear Medicine and Molecular Imaging.